Literature DB >> 16124999

Chemokine receptor CXCR3: an unexpected enigma.

Liping Liu1, Melissa K Callahan, DeRen Huang, Richard M Ransohoff.   

Abstract

CXCR3, the receptor for CXCL9/MIG, CXCL10/IP-10, and CXCL11/I-TAC, is preferentially expressed on activated Th1 T cells and has been predicted to play an important role in their trafficking. However, this simplistic view of the function of CXCR3 and its ligands has not been borne out by studies of disease models, including experimental autoimmune encephalomyelitis (EAE), using varied methods of receptor blockade, as well as knockout or transgenic mice. This review focuses on the current understanding of the enigmatic role of CXCR3 and its ligands in CNS inflammatory/autoimmune disorders. The conflicting results among varied models of CNS inflammation suggest complex and multiple roles for CXCR3 and its ligands in the pathogenesis of CNS inflammatory/autoimmune diseases. Thus, further study is needed to determine how CXCL10 neutralizing agents or CXCR3 receptor antagonists might be applied to treating human disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16124999     DOI: 10.1016/S0070-2153(05)68006-4

Source DB:  PubMed          Journal:  Curr Top Dev Biol        ISSN: 0070-2153            Impact factor:   4.897


  60 in total

1.  Characterization of mononuclear phagocytic cells in medaka fish transgenic for a cxcr3a:gfp reporter.

Authors:  Narges Aghaallaei; Baubak Bajoghli; Heinz Schwarz; Michael Schorpp; Thomas Boehm
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

Review 2.  Functional role of chemokines in liver disease models.

Authors:  Hacer Sahin; Christian Trautwein; Hermann E Wasmuth
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-26       Impact factor: 46.802

3.  CXCL10 is required to maintain T-cell populations and to control parasite replication during chronic ocular toxoplasmosis.

Authors:  Kazumi Norose; Akitoshi Kikumura; Andrew D Luster; Christopher A Hunter; Tajie H Harris
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-21       Impact factor: 4.799

4.  Migration and chemokine receptor pattern of colitis-preventing DX5+NKT cells.

Authors:  Matthias Hornung; Jens M Werner; Stefan Farkas; Hans J Schlitt; Edward K Geissler
Journal:  Int J Colorectal Dis       Date:  2011-06-07       Impact factor: 2.571

5.  Maternal serum concentrations of the chemokine CXCL10/IP-10 are elevated in acute pyelonephritis during pregnancy.

Authors:  Francesca Gotsch; Roberto Romero; Jimmy Espinoza; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Offer Erez; Nandor Gabor Than; Samuel Edwin; Moshe Mazor; Bo Hyan Yoon; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2007-10

6.  CXCR3 controls T-cell accumulation in fat inflammation.

Authors:  Viviane Zorzanelli Rocha; Eduardo J Folco; Cafer Ozdemir; Yuri Sheikine; Thomas Christen; Galina K Sukhova; Eva H C Tang; Marcio Sommer Bittencourt; Raul D Santos; Andrew D Luster; David E Cohen; Peter Libby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-05-08       Impact factor: 8.311

7.  Type I interferon signaling exacerbates Chlamydia muridarum genital infection in a murine model.

Authors:  Uma M Nagarajan; Daniel Prantner; James D Sikes; Charles W Andrews; Anna M Goodwin; Shanmugam Nagarajan; Toni Darville
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

8.  The emerging role of CXCL10 in cancer (Review).

Authors:  Mingli Liu; Shanchun Guo; Jonathan K Stiles
Journal:  Oncol Lett       Date:  2011-05-09       Impact factor: 2.967

Review 9.  Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology.

Authors:  Richard M Ransohoff
Journal:  Immunity       Date:  2009-11-20       Impact factor: 31.745

Review 10.  A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.

Authors:  Chris Mullins; M Scott Lucia; Simon W Hayward; Jeannette Y Lee; Jonathan M Levitt; Victor K Lin; Brian C-S Liu; Arul M Chinnaiyan; Mark A Rubin; Kevin Slawin; Robert A Star; Robert H Getzenberg
Journal:  J Urol       Date:  2008-02-20       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.